Navigating the Complex Maze of
LDL-Lowering Therapies


Viewer Survey
How long did you spend on this program?

Webcast CME Disclosure

Please read this notice and click the acknowledgement
at the bottom of the page to continue.

Program Medium

Internet-based program

Estimated Time to Complete Educational Activity

2.5 hours

Course Overview

In this web-based program, physicians will learn how recent developments in basic and clinical research have helped to advance the understanding of managing patients with hypercholesterolemia.

Release Date

December 9, 2016

Expiration Date

December 9, 2018

Method of Physician Participation Utilized in Learning Process

There are no fees for participating and receiving CME credit for this activity. During the period December 9, 2016 through December 9, 2018, participants must 1) read the learning objectives and faculty disclosures; 2) study the educational activity, and are expected to view all 5 segments totaling 2.5 hours to successfully complete the activity and earn CME credit; 3) register and complete the evaluation form and post-test; 4) score 100% on the post-test; and 5) print out your CME certificate.


Participation in this WebCAST is complimentary, and clinicians are invited to view this CME-certified program and/or share this invitation with other colleagues, departmental staff members, and healthcare professionals.

Grantor Support

Supported by an educational grant from Sanofi and Regeneron Pharmaceuticals

CME Credit provided by AKH Inc., Advancing Knowledge in Healthcare


This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Advancing Knowledge in Healthcare and CMEducation Resources, LLC. Advancing Knowledge in Healthcare is accredited by the ACCME to provide continuing medical education for physicians.

AKH Inc., Advancing Knowledge in Healthcare designates this live activity for a maximum of 2.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Physician Assistants NCCPA accepts AMA PRA Category 1 Credit™ from organizations accredited by ACCME

Disclosure of Conflicts of Interest

(AKH) requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to AKH policy. The existence or absence of COI for everyone in a position to control content will be disclosed to participants prior to the start of each activity

Program Faculty and Disclosure

Dorothy Caputo, MA, BSN, RN, Lead Nurse Planner/Reviewer: has disclosed no relevant financial relationships.
Patricia Brignoni, AKH Project Manager/Reviewer: has disclosed no relevant financial relationships.
Kelly Kraines, AKH Senior Director - Projects and Planning, Planner/Reviewer: has disclosed no relevant financial relationships.

Educational Objectives

Upon completion of this activity, participants will be able to:

  • Detail the mechanisms, trials, and translational implications of identifying new LDL targets that have the potential for producing LDL reductions above those that can be achieved with current statin-lowering agents;
  • Utilize multiple pharmacologic agents—including statins, ezetimibe, and PCSK9 inhibitors in real world situations in patients with LDL levels that place them at risk for CVD;
  • Recognize patients with statin-linked intolerance, including identification of patients with SAMS, and those who are sub-optimally responsive to statin therapy; and, apply the clinical treatment roadmap for patients who require intensification of LDL-lowering therapy with PCSK9 inhibitors and/or other agents;
  • Manage high risk patients and special populations—diabetes, HeFH, and others—with LDL elevations with newly available therapies and individualize case management of patients with hypercholesterolemia at the front lines of CV care;
  • Explain why, when, and in whom PCSK9 inhibition is an appropriate LDL-lowering agent, either alone or in combination with statins, in the setting of diabetes, CAD, stroke, elevated DV risk, HeFH and other subgroups with inappropriately high LDL levels.

Hardware and Software Requirements:

To participate in this program, viewers must have a PC or Macintosh computer that has active, ongoing internet access for the duration of the program, as well as a compatible Flash-viewer. An email address is required for registration, and a printer is required to print out the CME certificate.

Privacy Policy

When you participate in a CME activity offered by CMEducation Resources, we ask you for your name, degree, affiliation, street address, telephone number, fax number, and/or e-mail address (the "Information"). We use that Information in the following ways:

  • We use the Information to grade your post-test and to send you a certificate of completion of the CME activity. If we use a third-party company to grade your post-test and issue certificates of completion, we will give the Information to that company for that purpose only.
  • For each CME activity that you take, you must complete an evaluation questionnaire. That questionnaire asks if you are willing to participate in a follow-up survey. If you answer yes, we will use your name and contact information to send you the survey.
  • We may use the Information to send you information about other CME activities that CMEducation Resources is offering.
  • If our company is acquired by or merged into another company, we may make the Information available to the new owner/entity to use in the ways described above, to enable it to continue our business.
  • You should check this privacy policy periodically to see whether we have made any changes.


Copyright © 2016 by CMEducation Resources, LLC All rights reserved.

Reproduction, distribution, or translation without express written permission is strictly prohibited.

Content on this webcast reflects the opinions, output, and analyses of experts, investigators, educators, and clinicians whose activities for, while independent, are commercially supported by the sponsor noted at the start of each activity.

Content on this webcast is not meant to be, nor substitute for national guidelines or recommendations generated by professional, academic societies, colleges, or associations.

Content on this webcast is intended for educational value only. Its contents, analyses, and any recommendation made herein are intended to make scientific information and opinion available to health professionals, to stimulate thought, and further investigation. This webcast is not designed nor is any aspect of the contents here intended to provide advice regarding medical diagnosis or treatment for any individual case. Any decisions regarding diagnosis and/or management of any individual patient or group of patients should be made on individual basis after having consulted appropriate sources, whether they be appropriate consultants and/or guidelines and recommendations issued by national organizations, professional societies, governmental health organizations, or similar bodies. This webcast is not intended for use by the layman.

Opinions expressed herein are not necessarily those of CMEducation Resources, LLC, program supporters or accreditors, but reflect the opinions and analyses of the experts who have authored the material. Mention of products or services does not constitute endorsement. Clinical, legal, financial, and other comments are offered for general guidance only; and professional counsel should be sought for all specific situations.
Copyright © CMEducation Resources, LLC.




I have read this CME information statement and wish to participate in this CME activity.

Copyright © CMEducation Resources, LLC



Key Program Topics Include:

Antisense Oligonucleaotide
Apo B
Apo B-100
Atorvastatin CETP

Dutch Lipid Clinic Network Diagnostic Criteria
Familial Hyperlipidemia


Microsomal Triglyceride Transport Protein
PCSK9 Inhibitors
REGN727 niacin

Simon Broome
tendon xanthoma
UK NICE FH Guidelinesdulation